| Vito Ferrucci, MD | |
|
833 Summer St, Suite 1b, Stamford, CT 06901 | |
| (203) 325-4665 | |
| (203) 359-0902 |
| Full Name | Vito Ferrucci |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 39 Years |
| Location | 833 Summer St, Stamford, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023101292 | NPI | - | NPPES |
| 001291517 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 029151 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stamford Hospital | Stamford, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physicians For Women's Health, Llc | 3274430665 | 278 |
News Archive
Integral Molecular, the industry leader in membrane protein technologies, was awarded a Small Business Innovation Research grant from the NIH to initiate a target discovery program for Alzheimer's disease.
With a new molecular imaging system powerful enough to peer down to 20-micrometer resolution, researchers can now use radioluminescence to examine the characteristics of single, unconnected cells. The result is a fascinating picture of diversity among cells previously assumed to behave the same, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Of all the licensing exams along the way to becoming an M.D., the Step 1 is notorious for having the worst national passage rate. By adopting a fully integrated medical curriculum in lieu of the traditional academic model, the University of Texas Medical Branch has seen a dramatic drop over the course of a decade in the failure rate, with underrepresented minority students benefiting the most, according to new research that will be presented April 30, 2010 at the annual meeting of the American Educational Research Association.
Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.
The landmark Framingham Heart Study (FHS) is launching a major initiative to discover risk factors and markers that could lead to new blood tests to identify individuals at high risk of heart disease and stroke.
› Verified 1 days ago
| Entity Name | Physicians For Women's Health, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801826680 PECOS PAC ID: 3274430665 Enrollment ID: O20031215000455 |
News Archive
Integral Molecular, the industry leader in membrane protein technologies, was awarded a Small Business Innovation Research grant from the NIH to initiate a target discovery program for Alzheimer's disease.
With a new molecular imaging system powerful enough to peer down to 20-micrometer resolution, researchers can now use radioluminescence to examine the characteristics of single, unconnected cells. The result is a fascinating picture of diversity among cells previously assumed to behave the same, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Of all the licensing exams along the way to becoming an M.D., the Step 1 is notorious for having the worst national passage rate. By adopting a fully integrated medical curriculum in lieu of the traditional academic model, the University of Texas Medical Branch has seen a dramatic drop over the course of a decade in the failure rate, with underrepresented minority students benefiting the most, according to new research that will be presented April 30, 2010 at the annual meeting of the American Educational Research Association.
Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.
The landmark Framingham Heart Study (FHS) is launching a major initiative to discover risk factors and markers that could lead to new blood tests to identify individuals at high risk of heart disease and stroke.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vito Ferrucci, MD 833 Summer St, Suite 1b, Stamford, CT 06901 Ph: (203) 325-4665 | Vito Ferrucci, MD 833 Summer St, Suite 1b, Stamford, CT 06901 Ph: (203) 325-4665 |
News Archive
Integral Molecular, the industry leader in membrane protein technologies, was awarded a Small Business Innovation Research grant from the NIH to initiate a target discovery program for Alzheimer's disease.
With a new molecular imaging system powerful enough to peer down to 20-micrometer resolution, researchers can now use radioluminescence to examine the characteristics of single, unconnected cells. The result is a fascinating picture of diversity among cells previously assumed to behave the same, revealed researchers at the Society of Nuclear Medicine and Molecular Imaging's 2014 Annual Meeting.
Of all the licensing exams along the way to becoming an M.D., the Step 1 is notorious for having the worst national passage rate. By adopting a fully integrated medical curriculum in lieu of the traditional academic model, the University of Texas Medical Branch has seen a dramatic drop over the course of a decade in the failure rate, with underrepresented minority students benefiting the most, according to new research that will be presented April 30, 2010 at the annual meeting of the American Educational Research Association.
Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.
The landmark Framingham Heart Study (FHS) is launching a major initiative to discover risk factors and markers that could lead to new blood tests to identify individuals at high risk of heart disease and stroke.
› Verified 1 days ago
Dr. Scott A. Cole, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1 Hospital Plz, Stamford, CT 06902 Phone: 203-276-2030 Fax: 203-276-7908 | |
Brian Steven Sheets, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 992 High Ridge Rd, Stamford, CT 06905 Phone: 203-321-1300 Fax: 203-321-8462 | |
Dr. Richard Roger Viscarello Jr., M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1275 Summer Street, Suite 306, Stamford, CT 06905 Phone: 203-978-5775 Fax: 203-978-5777 | |
Dr. Antonios J Panagiotakis, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1275 Summer St, Stamford, CT 06905 Phone: 203-353-9099 Fax: 203-353-9699 | |
Sarah S Kim, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Hospital Plz, Stamford, CT 06902 Phone: 203-276-7133 Fax: 203-276-7908 | |
Katherine S Shaio, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 292 Long Ridge Rd, Suite 202, Stamford, CT 06902 Phone: 203-276-4524 Fax: 203-276-4525 |